Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Reaches New 12-Month High – Time to Buy?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $42.2150 and last traded at $41.32, with a volume of 200 shares traded. The stock had previously closed at $36.5850.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Danske lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, February 19th. BNP Paribas Exane upgraded Swedish Orphan Biovitrum to an “outperform” rating in a research note on Tuesday, February 10th. Finally, Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Swedish Orphan Biovitrum has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

The firm has a market capitalization of $14.71 billion, a PE ratio of 317.87 and a beta of 0.36. The company has a debt-to-equity ratio of 0.14, a current ratio of 0.90 and a quick ratio of 0.59. The stock has a 50-day moving average price of $36.61 and a 200-day moving average price of $34.06.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Swedish Orphan Biovitrum had a return on equity of 15.74% and a net margin of 1.43%.The firm had revenue of $846.23 million during the quarter, compared to the consensus estimate of $879.40 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.